Liposomal Bupivacaine in Benign Soft Tissue Tumor Resection
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Liposomal bupivacaine (Exparel) has been used as an adjunct to pain management in the
perioperative setting. However, the efficacy of the drug has not bewen studied in patients
with benign soft tissue tumor resections. The goal of the study is to see if Exparel controls
pain and improves functional outcomes for patients after these procedures compared to the
current standard Bupivacaine HCL.